Genetic Technologies (ASX:GTG, NASDAQ:GENE) is preparing to reveal details of a capital raising. The ASX has granted the company a trading halt to organise.
GTG is a molecular diagnostics company, with its lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.
The halt will remain in place until the opening of trade on Tuesday 10th March 2015, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.